Related Experiment Video

Updated: May 15, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Propranolol for hemangiomas

Mahmudul Hasan1, Matiur Rahman, Shafiqul Hoque

  • 1Pediatric Surgery, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh. t_mh@live.com

Pediatric Surgery International
|December 19, 2012
PubMed

Insights

Oral propranolol effectively treats infantile hemangiomas, showing rapid regression within months. This study confirms propranolol

Area of Science:

  • Pediatric Oncology
  • Dermatology
  • Pharmacology

Background:

  • Infantile hemangiomas are common benign tumors in children.
  • Approximately 10% of hemangiomas cause significant morbidity, requiring medical intervention.

Purpose of the Study:

  • To evaluate the efficacy and safety of propranolol for treating infantile hemangiomas.
  • To observe the adverse effects of oral propranolol in pediatric patients.

Main Methods:

  • 36 children received oral propranolol at 3 mg/kg/day, divided into three doses.
  • Blood pressure and heart rate were monitored during initial treatment.
  • Hemangioma changes were assessed using visual analog scale with pre- and post-treatment photographs.

Main Results:

  • All cases showed immediate improvement in color and growth, particularly extensive lesions.
  • Clinical regression was observed within 30 days, with complete regression in 7 months.
  • The average treatment duration was 4.1 months.

Conclusions:

  • Oral propranolol at 3 mg/kg/day demonstrates rapid stabilization and early regression of infantile hemangiomas.
  • The treatment exhibited a favorable safety profile.
  • Propranolol is an effective therapeutic option for infantile hemangiomas.
Abstract

More Related Videos

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...